Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
Status:
Recruiting
Trial end date:
2022-11-29
Target enrollment:
Participant gender:
Summary
Investigators aim is to conduct an RCT to study the effect of adjunct metformin treatment to
insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin
secretion. The patients will be randomly allocated to metformin or placebo treatment for 4
months